Adenosine A2B Receptors
Adenosine A2B receptors are members of the adenosine receptor group of G-protein-coupled receptors that also includes A1, A2A and A3. A2B receptors display high expression levels in the cecum, colon and bladder, with lower levels in the lung, blood vessels and eye.
Adenosine A2B Receptor Agonists |
|
|---|---|
| Cat. No. | Product Name / Activity |
| 4472 | BAY 60-6583 |
| Potent partial A2B agonist; cardioprotective | |
| 4603 | LUF 5834 |
| Potent adenosine A2A and A2B receptor partial agonist | |
Adenosine A2B Receptor Antagonists |
|
| Cat. No. | Product Name / Activity |
| 4727 | GS 6201 |
| Selective A2B antagonist | |
| 2752 | MRS 1754 |
| Selective A2B antagonist | |
| 3199 | PSB 0788 |
| Selective A2B antagonist | |
| 2009 | PSB 1115 |
| Selective human A2B antagonist; water-soluble | |
| 3198 | PSB 603 |
| Highly selective A2B antagonist | |
Adenosine A2B Receptor Modulators |
|
| Cat. No. | Product Name / Activity |
| 6787 | KI-7 |
| Positive allosteric modulator of A2B receptors | |
Other |
|
| Cat. No. | Product Name / Activity |
| 7954 | CELT-327 |
| Potent and selective hA2B/A3 adenosine receptor fluorescent antagonist | |
Adenosine A2B receptors are members of the adenosine receptor group of G-protein-coupled receptors that also includes A1, A2A and A3. A2B receptors display high expression levels in the cecum, colon and bladder, with lower levels found in the lung, blood vessels, eye, median eminence and mast cells. A2B receptors play a role in the relaxation of smooth muscle in the vasculature and intestines, inhibit monocyte and macrophage function and stimulate mast cell mediator release. The human A2B receptor gene is localized on chromosome 17 (17p12-p11.2).
Both A2A and A2B receptors are important in cancer immunology. The tumor microenvironment is hypoxic, which promotes the expression of CD39 and CD73 by immune cells. CD39 and CD73 are ectonucleotidases that convert ATP to adenosine, elevating concentrations of adenosine locally. Adenosine is a crucial mediator of altered immune function in cancer as it binds A2A and A2B receptors on lymphocytes silencing the antitumor immune response.